Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) and Sanofi (NYSE: SNY) announced that two placebo-controlled Phase 3 studies evaluating investigational dupilumab in ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Regeneron (REGN) PT Lifted to $523 at Leerink PartnersApril 4, 2016 6:21 AM Regeneron (REGN) Shares Cross Above $400 LevelApril 1, 2016 12:12 PM Baird Reiterates Outperform on Regeneron (REGN) Following Positive Phase III DataApril 1, 2016 11:52 AM Roth Expects Full Approval of Regeneron (REGN) Dupilumab, Trims PT to $520 April 1, 2016 10:55 AM Regeneron and Sanofi Announce Positive Dupilumab Topline Results from Two Phase 3 Trials in Inadequately Controlled Moderate-to-Severe Atopic Dermatitis PatientsApril 1, 2016 1:00 AM